Literature DB >> 21378593

Meropenem/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis.

Nicolas Dauby1, Inge Muylle, Françoise Mouchet, Roger Sergysels, Marie-Christine Payen.   

Abstract

The combination of meropenem with clavulanate has high antimycobacterial activity in vitro against extensively drug-resistant Mycobacterium tuberculosis strains. We report the successful use of this combination in association with linezolid in the management of an advanced extensively drug-resistant tuberculosis disease with complex second-line drug resistance in a 14-year-old teenager.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21378593     DOI： 10.1097/INF.0b013e3182154b05

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  23 in total

Review 1.  Advances in the development of new tuberculosis drugs and treatment regimens.

Authors:  Alimuddin Zumla; Payam Nahid; Stewart T Cole
Journal:  Nat Rev Drug Discov       Date:  2013-05       Impact factor: 84.694

2.  Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.

Authors:  L Davies Forsman; C G Giske; J Bruchfeld; T Schön; P Juréen; K Ängeby
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

Review 3.  Drug-resistance in Mycobacterium tuberculosis: where we stand.

Authors:  Amanda Mabhula; Vinayak Singh
Journal:  Medchemcomm       Date:  2019-06-11       Impact factor: 3.597

4.  Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

Authors:  Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth
Journal:  Am J Respir Crit Care Med       Date:  2019-11-15       Impact factor: 21.405

5.  Rapid cytolysis of Mycobacterium tuberculosis by faropenem, an orally bioavailable β-lactam antibiotic.

Authors:  Neeraj Dhar; Vincent Dubée; Lluis Ballell; Guillaume Cuinet; Jean-Emmanuel Hugonnet; François Signorino-Gelo; David Barros; Michel Arthur; John D McKinney
Journal:  Antimicrob Agents Chemother       Date:  2014-11-24       Impact factor: 5.191

6.  Identification of Mycobacterial Genes Involved in Antibiotic Sensitivity: Implications for the Treatment of Tuberculosis with β-Lactam-Containing Regimens.

Authors:  Gopinath Viswanathan; Sangya Yadav; Tirumalai R Raghunand
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

7.  Combinatorial active-site variants confer sustained clavulanate resistance in BlaC β-lactamase from Mycobacterium tuberculosis.

Authors:  Philippe Egesborg; Hélène Carlettini; Jordan P Volpato; Nicolas Doucet
Journal:  Protein Sci       Date:  2014-12-30       Impact factor: 6.725

Review 8.  Drug-Resistant Tuberculosis: Challenges and Progress.

Authors:  Sebastian G Kurz; Jennifer J Furin; Charles M Bark
Journal:  Infect Dis Clin North Am       Date:  2016-06       Impact factor: 5.982

9.  Map the gap: missing children with drug-resistant tuberculosis.

Authors:  C M Yuen; C A Rodriguez; S Keshavjee; M C Becerra
Journal:  Public Health Action       Date:  2015-03-21

Review 10.  Reappraising the use of β-lactams to treat tuberculosis.

Authors:  Sebastian G Kurz; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2012-09       Impact factor: 5.091
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.